{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:29Z","timestamp":1789154429222,"version":"build-2803163510"},"reference-count":12,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and is commonly used in the treatment of prostate cancer, but it can cause various endocrine side effects, especially if not used concurrently with the appropriate treatment. The clinical implications of this adverse event and management strategies are discussed here in this case report to raise awareness about this potential risk in patients with prostate cancer undergoing treatment with abiraterone acetate, especially when used in an erroneous manner without monitoring.<\/jats:p>","DOI":"10.3390\/curroncol32030156","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T05:46:52Z","timestamp":1741585612000},"page":"156","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids"],"prefix":"10.3390","volume":"32","author":[{"given":"Ahmed S.","family":"Mohamed","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad R.","family":"Awwad","sequence":"additional","affiliation":[{"name":"Transitional Year Program, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel Ann","family":"Chacko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3268-6801","authenticated-orcid":false,"given":"Shraboni","family":"Dey","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Braithwaite","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Bhuju","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Elias","sequence":"additional","affiliation":[{"name":"Internal Medicine Program, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpuro1237","article-title":"CYP17 inhibition as a hormonal strategy for prostate cancer","volume":"5","author":"Reid","year":"2008","journal-title":"Nat. Clin. Pract. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0889-8529(08)70021-5","article-title":"The genetics, pathophysiology, and management of human deficiencies of P450c17","volume":"30","author":"Auchus","year":"2001","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1210\/jcem-71-1-86","article-title":"Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency","volume":"71","author":"Moreira","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"Judson","year":"2004","journal-title":"Br. J. Cancer."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"luad039","DOI":"10.1210\/jcemcr\/luad039","article-title":"Abiraterone-Induced Endocrinopathies","volume":"1","author":"Decamps","year":"2023","journal-title":"JCEM Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000501640","article-title":"Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review","volume":"97","author":"Baloch","year":"2019","journal-title":"Oncology"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:49:50Z","timestamp":1760028590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/3\/156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["curroncol32030156"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32030156","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}